Physician profile
Daniel Patrick Marinelli
NPI 1841813300
$2,544.14
in general payments reported to CMS, 2019-2025
18 companies · $604 in 2025
The $604 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $331 · 2022: $501 · 2023: $448 · 2024: $659 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,711.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $377.40 | 2021-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $311.01 | 2021-2025 | Brilinta, Farxiga, Bevespi Aerosphere |
| Novartis Pharmaceuticals Corporation | $239.55 | 2021-2025 | |
| Boston Scientific Corporation | $235.74 | 2023-2025 | Watchman Flx |
| Pfizer INC. | $213.78 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $210.99 | 2021-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $164.60 | 2022-2025 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $163.31 | 2023-2024 | Inpefa |
| Merck Sharp & Dohme LLC | $148.67 | 2022-2025 | Verquvo, Capvaxive |
| Novo Nordisk INC | $141.84 | 2021-2025 | Wegovy, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.73 | 2021-2025 | Jardiance |
| Scpharmaceuticals INC. | $66.73 | 2023-2025 | |
| Esperion Therapeutics, INC. | $54.53 | 2024-2025 | Nexletol |
| Medtronic, INC. | $32.73 | 2024 | Cobalt Dr Mri Surescan |
| Alnylam Pharmaceuticals INC. | $31.18 | 2024 | Onpattro |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $23.66 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.57 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.12 | 2024 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Marinelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.